Atossa Genetics, Inc. To Exhibit At Two Medical Conferences

SEATTLE, WA--(Marketwired - April 28, 2015) -

Atossa Genetics Inc. (NASDAQ: ATOS), announced today that they will exhibit at two upcoming medical conferences: American Society of Breast Surgeons (ASBS) Meeting held in Orlando, Florida April 29-May 3, 2015 and the American Congress of Obstetricians and Gynecologists (ACOG) Meeting to be held May 2-6, 2015 in San Francisco, California. Atossa will be featuring the FullCYTE Breast Aspirator device, which is used to collect nipple aspirate fluid for cytological analysis at a laboratory. The National Reference Laboratory for Breast Health, Inc., Atossa’s subsidiary, will also exhibit at the ACOG meeting showcasing its pharmacogenetic test offering.

About Atossa Genetics

Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. The laboratory services and the Company’s medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory approvals needed by Atossa to sell its products, responses to regulatory matters, Atossa’s ability to achieve its objectives, continue to manufacture and sell its products, recalls of products, the safety and efficacy of Atossa’s products and services, performance of distributors, whether Atossa can launch and commercialize in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. Atossa does not undertake any obligation to update any forward looking statement.